Main Article Content

Ariska Deffy Anggarany
Wafa
Rifaldi Saputra

Page: 2223-2234

Abstract

Introduction: Renal impairment affects the pharmacokinetics of various antibiotics eliminated through the renal route, potentially leading to drug accumulation, toxicity, or therapeutic failure if doses are not appropriately adjusted. The variability in antibiotic response in this population remains a clinical challenge due to the complexity of pharmacokinetic/pharmacodynamic (PK/PD) parameters, degree of renal dysfunction, comorbidities, and dosing strategies. Objective: This systematic review aims to explore the relationship between clinical pharmacokinetic parameters and antibiotic response variability in adult patients with renal impairment, as well as to identify implementable PK/PD-based individualized therapy strategies. Methods: A literature search was conducted through PubMed/MEDLINE, Scopus, Embase, and Cochrane Library (2016–2026) following PRISMA 2020 guidelines. Studies involving adult patients (≥18 years) with renal impairment that reported PK/PD parameters and clinical outcomes were included. A narrative synthesis was performed on 18 articles meeting the inclusion criteria. Results: Renal function is a major determinant of antibiotic exposure, particularly for renally eliminated drugs. PK/PD parameters such as AUC/MIC, trough concentration, and %fT>MIC play important roles in assessing therapeutic adequacy, although their association with clinical outcomes is not always consistent due to population heterogeneity, infection severity, and differences in dosing strategies. Higher vancomycin exposure is consistently associated with an increased risk of nephrotoxicity. PK/PD-based individualized approaches through therapeutic drug monitoring, Bayesian forecasting, and model-informed precision dosing have been shown to improve target concentration attainment and reduce toxicity risk. Conclusion: Clinical pharmacokinetic parameters are associated with antibiotic response variability in patients with renal impairment, with more consistent relationships observed for toxicity than for efficacy. Integration of PK/PD-based individualized dosing strategies into routine clinical practice is necessary to optimize antibiotic therapy effectiveness and safety, supported by the development of comprehensive predictive models in this population.

Downloads

Download data is not yet available.

Article Details

How to Cite
Anggarany , A. D., Wafa, W., & Saputra , R. (2026). Clinical Pharmacokinetic Parameters and Antibiotic Response Variability in Patients with Renal Impairment: A Systematic Review . Journal of Pharmaceutical and Sciences, 9(3), 2223–2234. https://doi.org/10.36490/journal-jps.com.v9i3.1714
Section
Review Article

References

Valladales-Restrepo LF, Henao-Salazar JA, Mejía-Mejía I, Castro-Aragón DA, Rodríguez-Correa N, Oyuela-Gutiérrez MC, et al. Use of antibiotics in patients with chronic kidney disease: evidence from the real world. Expert Opin Drug Saf 2026;25:695–701. https://doi.org/10.1080/14740338.2024.2443780

Liu P, Capitano B, Stein A, El-Solh AA. Clinical outcomes of linezolid and vancomycin in patients with nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus stratified by baseline renal function: a retrospective, cohort analysis. BMC Nephrol 2017;18:168. https://doi.org/10.1186/s12882-017-0581-y

Ishigo T, Matsumoto K, Yoshida H, Tanaka H, Ibe Y, Fujii S, et al. Relationship between nephrotoxicity and area under the concentration–time curve of vancomycin in critically ill patients: a multicenter retrospective study. Microbiol Spectr 2024;12:e03739-23. https://doi.org/10.1128/spectrum.03739-23.

Matsuki Y, Sako K, Kozima Y, Watanabe T, Kashiwagura Y, Yasuno N, et al. Development and validation of a novel scoring model integrating clinical risk factors and pharmacokinetic parameters to predict vancomycin-induced nephrotoxicity. Pharmacotherapy 2026;46:e70111. https://doi.org/10.1002/phar.70111.

Kullar R, Wagenlehner FM, Popejoy MW, Long J, Yu B, Goldstein EJC. Does moderate renal impairment affect clinical outcomes in complicated intra-abdominal and complicated urinary tract infections? Analysis of two randomized controlled trials with ceftolozane/tazobactam. J Antimicrob Chemother 2017;72:900–905. https://doi.org/10.1093/jac/dkw486.

Udy AA, Dulhunty JM, Roberts JA, Davis JS, Webb SAR, Bellomo R, et al. Association between augmented renal clearance and clinical outcomes in patients receiving β-lactam antibiotic therapy by continuous or intermittent infusion: a nested cohort study of the BLING-II randomised, placebo-controlled, clinical trial. Int J Antimicrob Agents 2017;49:624–630. https://doi.org/10.1016/j.ijantimicag.2016.12.022

Shorr AF, Bruno CJ, Zhang Z, Jensen E, Gao W, Feng HP, et al. Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial. Crit Care 2021;25:354. https://doi.org/10.1186/s13054-021-03773-5.

Zamoner W, de Souza Cavalcante R, Balbi AL, Ponce D. Vancomycin administration and AUC/MIC in patients with acute kidney injury on hemodialysis (HD): randomized clinical trial. Sci Rep 2024;14:31220. https://doi.org/10.1038/s41598-024-82587-1.

Nakagawa R, Sato K, Uesaka Y, Mitsuki T, Kondo K, Wake A, et al. Cefepime-induced encephalopathy in end-stage renal disease patients. J Neurol Sci 2017;376:123–128. https://doi.org/10.1016/j.jns.2017.03.018.

Shahar S, Arimuthu DA, Mazlan SA. Ertapenem-induced neurotoxicity in an end-stage renal disease patient on intermittent haemodialysis: a case report. BMC Nephrol 2022;23:360. https://doi.org/10.1186/s12882-022-02980-8.

Zhang Y, Wang T, Zhang D, You H, Dong Y, Liu Y, et al. Therapeutic drug monitoring coupled with Bayesian forecasting could prevent vancomycin-associated nephrotoxicity in renal insufficiency patients: a prospective study and pharmacoeconomic analysis. Ther Drug Monit 2020;42:600–609. https://doi.org/10.1097/FTD.0000000000000750.

Sanz-Codina M, Bozkir HÖ, Jorda A, Zeitlinger M. Individualized antimicrobial dose optimization: a systematic review and meta-analysis of randomized controlled trials. Clin Microbiol Infect 2023;29:845–857. https://doi.org/10.1016/j.cmi.2023.03.018

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. https://doi.org/10.1136/bmj.n71.

Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:l4898. https://doi.org/10.1136/bmj.l4898.

Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016;355:i4919. https://doi.org/10.1136/bmj.i4919.

Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, et al. Systematic reviews of etiology and risk. In: Aromataris E, Munn Z, Editors. JBI Manual for Evidence Synthesis. Adelaide: JBI; 2020. https://doi.org/10.46658/JBIMES-20-08.

Wu W, Ke M, Ye L, Lin C. Application of physiologically based pharmacokinetic modeling to predict the pharmacokinetics of telavancin in obesity with renal impairment. Eur J Clin Pharmacol. 2021;77:989–998. https://doi.org/10.1007/s00228-020-03072-y.

Nakashima T, Koido K, Baba H, Otsuka R, Okinaka K, Sano T, Nishigaki R, Hashimoto H, Otsuka T, Esaki M, Terakado H. Contribution of pharmacists with expertise in infectious diseases to appropriate individualized vancomycin dosing. Pharmazie. 2018;73(7):422–424. https://doi.org/10.1691/ph.2018.8427.

Wang X, Wang Y, Yao F, Chen S, Hou Y, Zheng Z, Luo J, Qiu B, Li Z, Wang Y, Wu Z, Lan J, Chen C. Pharmacokinetics of linezolid dose adjustment for creatinine clearance in critically ill patients: a multicenter, prospective, open-label, observational study. Drug Des Devel Ther. 2021;15:2129–2141. https://doi.org/10.2147/DDDT.S303497.

Wang L, Yuan Q, Tan M, Xie S, Wu J, Song X, Wang C. Evaluation of efficacy and nephrotoxicity during vancomycin therapy: A retrospective study in China. Exp Ther Med. 2019;17(3):2389–2396. https://doi.org/10.3892/etm.2019.7188.

Cheng C, Akter F, Bozell H, Neumann T. Linezolid-induced lactic acidosis presenting as acute cholecystitis: a case report and systematic review. Cureus. 2024;16(10):e70794. https://doi.org/10.7759/cureus.70794.

Aitullina A, Krūmiņa A, Svirskis Š, Purviņa S. Colistin use in patients with extreme renal function: from dialysis to augmented clearance. Medicina (Kaunas). 2019;55(2):33. https://doi.org/10.3390/medicina55020033.

Saad R, Hallit S, Chahine B. Evaluation of renal drug dosing adjustment in chronic kidney disease patients at two university hospitals in Lebanon. Pharm Pract. 2019;17(1):1304.

Hassan Z, Ali I, Ullah AR, Ahmed R, Zar A, Ullah I, et al. Assessment of Medication Dosage Adjustment in Hospitalized Patients With Chronic Kidney Disease. Cureus. 2021;13(2):e13449. https://doi.org/10.7759/cureus.13449.

Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, Mueller BA, Pai MP, Wong-Beringer A, Rotschafer JC, Rodvold KA, Maples HD, Lomaestro BM. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the ASHP, IDSA, PIDS, and SIDP. Am J Health Syst Pharm. 2020;77(11):835–864. https://doi.org/10.1093/ajhp/zxaa036.